Cancer nanovaccine is a frontier
immunotherapy strategy, in which
the delivery carrier can protect antigen and adjuvant from degradation,
increase blood circulation half-life, and improve antigen permeability
and presentation, thus enhancing the security and potency of nanovaccine.
To address the barriers of antigen delivery, we design and fabricate
a kind of intracellular pH-sensitive glycopolypeptide coordinated
nanovaccine (OVA-HPGM-Mn) with ∼30% loading capacity of ovalbumin
(OVA). The nanovaccine OVA-HPGM-Mn could specifically deliver antigen
to dendritic cells (DCs) and effectively escape from endolysosomes
to cytoplasm after 6 h of incubation, while the blank counterpart
HPGM-Mn acted as an adjuvant to promote DCs maturation and increase
the percentage of maturated cells to 26.5% from 11.8% in vitro. Furthermore,
the mannosylated polypeptide nanovaccine prolonged the retention time
of OVA for 72 h to facilitate 29.5% DCs maturation in lymph nodes,
activated 48.8% CD8+T cells in spleen, increased the CD8+/CD4+T cell ratio twice to 1.06, and upregulated
the levels of pro-inflammatory cytokines including TNF-α, IFN-γ,
and IL-6, thus inhibiting the tumor growth of ∼80%. Consequently,
this work provides a versatile strategy for the fabrication of glycosylated
polypeptide coordinated nanomaterials for antigen delivery and cancer
immunotherapy.